Swedbank AB Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

Swedbank AB acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,524,000.

Other hedge funds also recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its position in Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after purchasing an additional 24,444 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Xenon Pharmaceuticals by 3.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock valued at $183,110,000 after buying an additional 140,149 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after buying an additional 1,435,096 shares during the last quarter. Capital International Investors grew its stake in shares of Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after buying an additional 233,466 shares in the last quarter. Finally, Commodore Capital LP grew its stake in shares of Xenon Pharmaceuticals by 30.1% in the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after buying an additional 700,000 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Down 2.9%

Shares of XENE stock traded down $2.04 during trading on Friday, reaching $68.92. 1,535,878 shares of the company’s stock were exchanged, compared to its average volume of 1,830,298. Xenon Pharmaceuticals Inc. has a twelve month low of $30.00 and a twelve month high of $72.66. The firm’s fifty day moving average price is $56.18 and its 200-day moving average price is $51.08. The stock has a market capitalization of $6.66 billion, a PE ratio of -14.66 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period last year, the company posted ($0.83) EPS. As a group, analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on XENE shares. Royal Bank Of Canada boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Wedbush decreased their price objective on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. JPMorgan Chase & Co. boosted their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Finally, Needham & Company LLC dropped their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of “Buy” and an average target price of $77.20.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.